Drug Insights

Master Tretinoin Search on Synapse

20 February 2024
2 min read

Vesanoid, also known as Tretinoin, is a vitamin A derivative that has been given the green light for treating acne vulgaris and specific forms of promyelocytic leukemia. This drug, originating from the pharmaceutical company Bausch Health Americas, acts as a RARs agonist that helps regulate gene expression and cell differentiation in a multifaceted manner, displaying a higher level of complexity in its mechanism of action. With its initial approval in the United States in 1971, Tretinoin has been increasingly incorporated into numerous over-the-counter products, due to its demonstrated efficacy in managing a wide range of skin conditions. Because of its reliability in the management of acne vulgaris, Tretinoin has gained widespread popularity among dermatologists and individuals seeking to alleviate this all-too-common skin condition. Its continued use in contemporary medicine reinforces Tretinoin's value as a valuable weapon in the struggle against acne and other cutaneous disorders, lending credence to its ongoing utility. Click on the image below to begin the exploration journey of Tretinoin through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Biogen's SKYCLARYS® Wins EU Approval: A Breakthrough for Friedreich’s Ataxia
Latest Hotspot
3 min read
Biogen's SKYCLARYS® Wins EU Approval: A Breakthrough for Friedreich’s Ataxia
20 February 2024
Biogen Secures European Commission for New Drug SKYCLARYS® (omaveloxolone), Pioneering Treatment for Friedreich’s Ataxia.
Read →
An analysis of Tinengotinib's R&D progress and its clinical results presented at the 2024 ASCO_GI Annual Meeting
An analysis of Tinengotinib's R&D progress and its clinical results presented at the 2024 ASCO_GI Annual Meeting
20 February 2024
Tinengotinib, a selective multi-kinase inhibitor, effectively targets FGFR2 fusion/rearrangement and resistance mutations in early trials involving cholangiocarcinoma patients.
Read →
CSL Unveils Phase 3 AEGIS-II Results on CSL112 (Apolipoprotein A-I) Efficacy and Safety
Latest Hotspot
3 min read
CSL Unveils Phase 3 AEGIS-II Results on CSL112 (Apolipoprotein A-I) Efficacy and Safety
20 February 2024
CSL Reveals Key Findings of Phase 3 AEGIS-II Study Assessing Effectiveness and Security of CSL112 (Human Apolipoprotein A-I).
Read →
Unveiling Clopidogrel: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Clopidogrel: How to Search for it on Synapse
20 February 2024
Clopidogrel Bisulfate, a medication trademarked as Plavix®, was approved by Bristol Myers Squibb in the US in 1997.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.